

Human vWF-A2 Antibody


Monoclonal Mouse IgG_{2B} Clone # 1072103 Catalog Number: MAB11543

DESCRIPTION	
Species Reactivity	Human
Specificity	Detects recombinant human VWF in Direct ELISA.
Source	Monoclonal Mouse IgG _{2B} Clone # 1072103
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	E. coli-derived recombinant human VWF Asp1498-Val1665 Accession # P04275
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose.

APPLICATIONS				
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.				
	Recommended	Sample		
	Concentration			
Immunohistochemistry	3-25 μg/mL	Immersion fixed paraffin-embedded		
		sections of human placenta		

DATA

Immunohistochemistry



Human Placenta. vWF-A2 was detected in immersion fixed paraffin-embedded sections of human placenta using Mouse Anti-Human vWF-A2 Monoclonal Antibody (Catalog # MAB11543) at 25 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm of endothelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Detection of vWF-A2 in

Reconstitution	Reconstitute lyophilized material at 0.2mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.	
Shipping	Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, s immediately at the temperature recommended below.	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.	
	 12 months from date of receipt, -20 to -70 °C as supplied. 	
	1 month, 2 to 8 °C under sterile conditions after reconstitution.	
	 6 months, -20 to -70 °C under sterile conditions after reconstitution. 	

Rev. 6/26/2024 Page 1 of 2

Bio-Techne®

Global | bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL: 1.612.379.2956

USA | TEL: 800.343.7475 **Canada |** TEL: 855.668.8722 **Europe | Middle East | Africa** TEL: +44.0.1235.529449

China | info.cn@bio-techne.com TEL: 400.821.3475



Human vWF-A2 Antibody

Monoclonal Mouse IgG_{2B} Clone # 1072103 Catalog Number: MAB11543

BACKGROUND

von Willebrand Factor (vWF) is a large, multimeric glycoprotein made by endothelial cells and megakaryocytes. The pre-pro-vWF protein contains 2813 amino acids (aa), which consists of 22 aa signal peptide, 741 aa propeptide, and mature vWF monomer of 2050 aa (1-4). The pro-vWF undergoes dimerization in the endoplasmic reticulum (ER) through C-terminal "cysteine-knot" (CK) domain. The pro-vWF dimmers are transported to Golgi and form multimers by forming disulfide bond in amino-terminal region of the mature form. The proteolytic processing of pro-region also occurs in Golgi. The matured vWF is stored in Weibel-Pallade bodies in endothelial cells and granules in megakaryocytes and platelets. The unusually-large vWF (ulvWF) multimers released from cells are very efficient in binding to platelets to form thrombus. The population of these highly active ulvWF multimers is controlled by a specific protease, ADAMTS13, which cleaves between residues Tyr1605 and Met1606 in the A2 domain of vWF. In the plasma, vWF appears as a series of large and intermediate multimers with molecular masses from several thousand to 500 kDa. vWF also performs hemostatic functions (3-5). In a high shear-stressed environment, vWF undergoes conformational change to expose a binding site for glycoprotein lbα. As a result, vWF facilitates aggregation of platelets. In addition to platelet binding, vWF binds coagulation factor VIII to increase the lifetime of FVIII in plasma. The purified rhvWF-A2 contains the A2 domain of vWF.

References:

- 1. Sadler, J.E. (1998) Annu. Rev. Biochem. 67:395.
- 2. Ruggeri, Z.M. (2003) Cur. Opin. Hemat. 10:142.
- 3. Michiels, J.J. et al. (2006) Clin. Appl. Thromb. Hemost. 12:397.
- 4. Groot, E. et al. (2007) Cur. Opin. Hemat. 14:284.
- 5. Lenting, P.J. et al. (2007) J. Thromb. Haemos. 5:1353.